Inactive Instrument

Highlights Tiger X Medical Inc Other OTC

Equities

US88677A1043

End-of-day quote Other OTC Other stock markets
- ^USD	-

May. 01	BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial	CI
Apr. 30	Transcript : BioCardia, Inc. - Special Call

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial	May. 01	CI
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	Apr. 25	CI
BioCardia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
BioCardia, Inc. and StemCardia, Inc. Announce Long-Term Partnership to Advance StemCardia?s Investigational Pluripotent Stem Cell Product Candidate for Treatment of Heart Failure	Mar. 13	CI
BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	Mar. 12	CI
Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	Mar. 04	CI
BioCardia, Inc. Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA	Feb. 08	CI
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction	Dec. 19	CI
BioCardia, Inc. Announces Expected Cardiamp Heart Failure Japan Approval Based on Pharmaceutical and Medical Device Agency Consultation Minutes	Dec. 18	CI
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure	Nov. 29	CI
BioCardia, Inc. Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure	Nov. 14	CI
Earnings Flash (BCDA) BIOCARDIA Posts Q3 Revenue $357,000	Nov. 08	MT
BioCardia, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Biocardia, Inc. Announces Completion of Enrollment in Phase Iii Cardiamp Hf Trial and Plans for Cardiamp Hf Trial Ii	23-10-11	CI
BioCardia, Inc. Announces Clarification and Next Steps on Its Autologous CardiAMP Cell Therapy Programs	23-09-06	CI
Biocardia, Inc. Announces Interim Efficacy Results in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial	23-09-05	CI
Earnings Flash (BCDA) BIOCARDIA Posts Q2 Revenue $43,000, vs. Street Est of $0.18M	23-08-09	MT
BioCardia, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Biocardia, Inc. Announces Dsmb Recommendation to Pause New Enrollment in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial While Additional Blinded Data Is Collected	23-07-24	CI
BioCardia Seeks CardiAMP Cell Therapy System Approval From Japan's Pharmaceutical Regulator	23-07-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Tiger X Medical Inc Other OTC

Equities

US88677A1043

Highlights

Filters